Table 3.
Lymphocyte subsets during the first year of treatment
| Total cohort | Treated | Treatment-naive |
Treated vs naive p value^ |
With early inflammatory activity | Without early inflammatory activity |
With vs without early inflammatory activity p value° |
|
|---|---|---|---|---|---|---|---|
| Baseline | |||||||
| Available, n | 73 | 55 | 18 | 17 | 56 | ||
| Leukocytes, N/mm3 | 6273 (2262) | 6064 (2208) | 6913 (2368) | 0.254 | 6501 (3232) | 6205 (1908) | 0.522 |
| Lymphocyte, N/mm3 | 1793 (771) | 1680 (801) | 2139 (557) | 0.050 | 2030 (1188) | 1721 (587) | 0.088 |
| CD3 + , N/mm3 | 1259 (602) | 1158 (624) | 1568 (404) | 0.022* | 1452 (879) | 1201 (484) | 0.085 |
| CD4 + , N/mm3 | 807 (446) | 742 (463) | 1006 (323) | 0.047* | 922 (641) | 772 (367) | 0.172 |
| CD8 + , N/mm3 | 439 (214) | 411 (224) | 526 (153) | 0.088 | 515 (263) | 416 (193) | 0.064 |
| CD19 + , N/mm3 | 291 (257) | 289 (244) | 299 (303) | 0.960 | 334 (366) | 279 (217) | 0.407 |
| 6 months | |||||||
| Available, n | 73 | 55 | 18 | 17 | 56 | ||
| Leukocytes, N/mm3 | 5712 (1666) | 5681 (1737) | 5806 (1469) | 0.870 | 5991 (1386) | 5627 (1745) | 0.209 |
| Lymphocyte, N/mm3 | 1388 (547) | 1306 (554) | 1639 (451) | 0.036* | 1564 (666) | 1335 (501) | 0.049* |
| CD3 + , N/mm3 | 1122 (505) | 1042 (508) | 1367 (419) | 0.027* | 1327 (617) | 1060 (454) | 0.014* |
| CD4 + , N/mm3 | 714 (367) | 652 (366) | 903 (309) | 0.016* | 824 (446) | 680 (338) | 0.046* |
| CD8 + , N/mm3 | 369 (192) | 352 (196) | 421 (176) | 0.305 | 484 (214) | 334 (173) | 0.001** |
| CD19 + , N/mm3 | 19 (32) | 23 (36) | 7 (11) | 0.084 | 29 (46) | 17 (27) | 0.495 |
| 12 months | |||||||
| Available, n | 61 | 45 | 16 | 11 | 50 | ||
| Leukocytes, N/mm3 | 6306 (2704) | 6296 (3055) | 6334 (1314) | 0.912 | 5432 (1499) | 6532 (2926) | 0.482 |
| Lymphocyte, N/mm3 | 1488 (655) | 1359 (669) | 1868 (476) | 0.022* | 1513 (561) | 1528 (661) | 0.584 |
| CD3 + , N/mm3 | 1204 (524) | 1091 (496) | 1525 (476) | 0.012* | 1233 (493) | 1211 (533) | 0.469 |
| CD4 + , N/mm3 | 780 (356) | 695 (328) | 1020 (330) | 0.003* | 760 (320) | 794 (365) | 0.759 |
| CD8 + , N/mm3 | 397 (224) | 370 (228) | 471 (199) | 0.251 | 456 (314) | 387 (201) | 0.199 |
| CD19 + , N/mm3 | 25 (70) | 32 (81) | 5 (7) | 0.267 | 11 (14) | 28 (78) | 0.314 |
^Multivariate ANCOVA corrected for age, sex, MS phenotype
°Multivariate ANCOVA corrected for age, sex, MS phenotype, and last DMT before ocrelizumab initiation
* Uncorrected p < 0.05
**Bonferroni p < 0.0028